Stocktoria
PFIZER INC PFE
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1944-01-17
PFIZER INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $62.6B | $63.6B | $59.6B | $101.2B | $81.3B |
| SG&A expense | $13.8B | $14.7B | $14.8B | $13.7B | $12.7B |
| Interest expense | $2.7B | $3.1B | $2.2B | $1.2B | $1.3B |
| Income tax | -$266.0M | -$28.0M | -$1.1B | $3.3B | $1.9B |
| Net income | $7.8B | $8.0B | $2.1B | $31.4B | $22.0B |
| EPS (diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Operating cash flow | $11.7B | $12.7B | $8.7B | $29.3B | $32.9B |
| Free cash flow | $9.1B | $9.8B | $4.8B | $26.0B | $30.2B |
| Cash & equivalents | $1.1B | $1.0B | $2.9B | $416.0M | $1.9B |
| Inventory | $10.7B | $10.9B | $10.2B | $9.0B | $9.1B |
| Total assets | $208.2B | $213.4B | $226.5B | $197.2B | $181.5B |
| Total liabilities | $121.4B | $124.9B | $137.2B | $101.3B | $104.0B |
| Shareholders' equity | $86.8B | $88.5B | $89.3B | $95.9B | $77.5B |
Source: SEC EDGAR filings · CIK 0000078003 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.